Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML

IntroductionProgressing myelodysplastic syndrome (MDS) into acute myeloid leukemia (AML) is an indication for hypomethylating therapy (HMA, 5-Azacytidine (AZA)) and a BCL2 inhibitor (Venetoclax, VEN) for intensive chemotherapy ineligible patients. Mouse models that engraft primary AML samples may fu...

Full description

Saved in:
Bibliographic Details
Main Authors: Petra Bašová, Lubomír Minařík, Silvia Carina Magalhaes-Novais, Jana Balounová, Zuzana Zemanová, Tatiana Aghová, Martin Špaček, Anna Jonášová, Kristýna Gloc Pimková, Jan Procházka, Radislav Sedláček, Tomáš Stopka
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
myelodysplastic syndrome
PDX (patient derived xenograft)
5-Azacytidine
Venetoclax (BCL2 inhibitor)
therapeutic targets
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1414950/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items